

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/838,136	04/20/2001	Reid W. von Borstel	1331-337	2922
7590 11/05/2003			EXAMINER	
Nixon & Vanderhye P.C.			KRISHNAN, GANAPATHY	
8th Floor 1100 N. Glebe Rd.			ART UNIT	PAPER NUMBER
Arlington, VA 22201			1623	
			DATE MAILED: 11/05/2003	17

Please find below and/or attached an Office communication concerning this application or proceeding.

· · · · · · · · · · · · · · · · · · ·						
· ·	Application No.	Applicant(s)				
	09/838,136	VON BORSTEL, REID W.				
Office Action Summary	Examiner	Art Unit				
	Ganapathy Krishnan	1623				
The MAILING DATE of this commun Period for Reply	ication appears on the c ver sheet	with the correspondence address				
A SHORTENED STATUTORY PERIOD F	OD DEDI V IS SET TO EXPIRE 3	MONTH(S) FROM				
THE MAILING DATE OF THIS COMMUNI - Extensions of time may be available under the provisions after SIX (6) MONTHS from the mailing date of this comn - If the period for reply specified above is less than thirty (3 - If NO period for reply is specified above, the maximum st - Failure to reply within the set or extended period for reply - Any reply received by the Office later than three months a earned patent term adjustment. See 37 CFR 1.704(b). Status	ICATION. of 37 CFR 1.136(a). In no event, however, may nunication. O) days, a reply within the statutory minimum of the atutory period will apply and will expire SIX (6) Me will, by statute, cause the application to become	a reply be timely filed hirty (30) days will be considered timely. ONTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).				
1) Responsive to communication(s) file	led on .					
,	2b)⊠ This action is non-final.					
	n for allowance except for formal m	natters, prosecution as to the merits is				
closed in accordance with the prac Disposition of Claims	tice under <i>Ex parte Quayl</i> e, 1935 (C.D. 11, 453 O.G. 213.				
4)⊠ Claim(s) <u>1-18,20-42,45 and 46</u> is/ar						
4a) Of the above claim(s) <u>1-18,20-40</u>	0,45 and 46 is/are withdrawn from o	consideration.				
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>41</u> is/are rejected.						
7)⊠ Claim(s) <u>42</u> is/are objected to.						
8) Claim(s) are subject to restrict	ction and/or election requirement.					
Application Papers						
9) The specification is objected to by the	<u></u>	. Ab . Evansia au				
10) The drawing(s) filed on is/are:						
Applicant may not request that any obj						
If approved, corrected drawings are re-		disapproved by the Examiner.				
12) The oath or declaration is objected to	•					
Priority under 35 U.S.C. §§ 119 and 120	by the Examiner.					
13) Acknowledgment is made of a claim	for foreign priority under 35 U.S.C.	8 119(a)-(d) or (f)				
a) ☐ All b) ☐ Some * c) ☐ None of:	Tor foreign priority under 60 0.0.0	. 3 110(4) (0) 01 (1).				
, , ,	documents have been received.					
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies						
	ational Bureau (PCT Rule 17.2(a))					
14) Acknowledgment is made of a claim for	or domestic priority under 35 U.S.C	C. § 119(e) (to a provisional application).				
a) ☐ The translation of the foreign lands 15)☐ Acknowledgment is made of a claim f						
Attachment(s)						
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PB) Information Disclosure Statement(s) (PTO-1449) Page 1	TO-948) 5) Notice of	w Summary (PTO-413) Paper No(s) of Informal Patent Application (PTO-152)				

Application/Control Number: 09/838,136

Art Unit: 1623

DETAILED ACTION

Applicant's election of Group V, Claims 41-42 in Paper No. 15 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Claims 1-18, 20-40, 45, 46 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in Paper No. 15.

An action on the merits of Claims 41 and 42 elected without traverse in Paper No. 15 is contained herein below.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claim 41 is rejected under 35 U.S.C. 102(e) as being anticipated by von Borstel et al (US 5736531)

The applied reference has a common inventor with the instant application. Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 102(e) might be overcome either by a showing under 37

Application/Control Number: 09/838,136

Art Unit: 1623

CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application and is thus not the invention "by another," or by an appropriate showing under 37 CFR 1.131.

Von Borstel et al drawn to compounds, compositions and methods of treatment and prevention of toxicity due to chemotherapeutic agents teach the use of acyl derivatives of uridine and cytidine (pyrimidine nucleotide precursor) for preventing or ameliorating the toxic effects of cancer chemotherapy agents. They teach the oral administration of triacetyl uridine for the amelioration of the toxicity of 5-fluorouracil (not a pyrimidine nucleoside analog, since it does not have a ribose unit) (see abstract, col. 5, lines 1-66). The dosage typically ranges from 0.5 to 20 grams per day and most commonly 2 to 10 grams per day (see col. 23, lines 55-59).

Conclusion

- 1. Claim 41 is rejected.
- 2. Claim 42, drawn to specific side effects is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ganapathy Krishnan whose telephone number is 703-305-4837. The examiner can normally be reached on 8.30am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 703-308-4624. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Application/Control Number: 09/838,136

Art Unit: 1623

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

GK

JAMES O. WILSON

SUPERVISORY PATENT EXAMINER